title: Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study.
abstract: Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare tumor typically affecting young women. It is an aggressive malignancy with a poor prognosis and few long-term survivors.
  
  
  OBJECTIVE
  Investigate the outcome of patients with SCCOHT.
  
  
  METHODS
  Data were collected for patients with SCCOHT treated in Australia, Canada and Europe. Information included stage, surgery, chemotherapy, radiotherapy, recurrence and survival.
  
  
  RESULTS
  The median follow-up is 13 months for all patients and 35.5 months in surviving patients. Ten patients had FIGO stage I tumors, six stage III tumors and one stage unknown. All underwent surgical resection. Adjuvant platinum-based chemotherapy was given to all patients. Seven received adjuvant radiotherapy with either pelvic and para-aortic radiotherapy, average dose 46.5 Gy (40 Gy/25# - 50.4 Gy/23#), or pelvic and whole abdominal radiotherapy, average dose 45 Gy to pelvis and 25 Gy (22.5 Gy/22# - 30 Gy/25#) to abdomen. The median survival for stage I tumors was not reached and was 6 months for stage III tumors. For the ten patients with stage I tumors: six received adjuvant radiotherapy with five alive and disease-free; four received no adjuvant radiotherapy with one alive and disease-free, while three have relapsed with one alive and disease-free after resection. Of the seven patients with stage III or unknown stage tumors, all but one have died. Recurrences were most frequent in the pelvis and the abdomen. Patients receiving salvage treatment with chemotherapy and radiotherapy did poorly.
  
  
  CONCLUSIONS
  We advocate a multi-modality treatment approach including surgery, chemotherapy with the addition of radiotherapy either sequentially or concurrently.
authors.affiliation: Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia.
authors.forename: M L
authors.initials: ML
authors.lastname: Harrison
authors.forename: P
authors.initials: P
authors.lastname: Hoskins
authors.forename: A
authors.initials: A
authors.lastname: du Bois
authors.forename: M
authors.initials: M
authors.lastname: Quinn
authors.forename: G J S
authors.initials: GJ
authors.lastname: Rustin
authors.forename: J A
authors.initials: JA
authors.lastname: Ledermann
authors.forename: S
authors.initials: S
authors.lastname: Baron-Hay
authors.forename: M L
authors.initials: ML
authors.lastname: Friedlander
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000097:blood / Q000145:classification / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000473:pathology*; D007044:Hysterectomy; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood / Q000145:classification* / Q000473:pathology / Q000628:therapy*; D010052:Ovariectomy; D018714:Radiotherapy, Adjuvant; D016896:Treatment Outcome